Gilead Sciences (GILD) Capital Expenditures (2009 - 2026)

Gilead Sciences (GILD) has reported Capital Expenditures for 18 consecutive years, with $140.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Capital Expenditures rose 30.84% year-over-year to $140.0 million; the trailing twelve-month figure through Jun 2026 stood at $609.0 million (up 22.04% YoY), and the FY2025 full-year result was $563.0 million, up 7.65% from the prior year.
• Capital Expenditures rose to $140.0 million in Q2 2026 per GILD's latest filing, from $117.0 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $247.0 million in Q1 2022 and bottomed at $104.0 million in Q1 2025.
• Historically, Capital Expenditures has averaged $147.6 million across 5 years, with a median of $140.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures jumped 49.7% in 2022, then plunged 55.87% in 2023.
• Over 5 years, Capital Expenditures stood at $181.0 million in 2022, then gained by 18.78% to $215.0 million in 2023, then sank by 31.63% to $147.0 million in 2024, then surged by 39.46% to $205.0 million in 2025, then sank by 31.71% to $140.0 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $140.0 million, $117.0 million, and $205.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.